Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor.

Oncotarget

Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A.
PMID: 29050204
Oncotarget. 2017 Sep 01;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19.

The permanent defects in bone growth observed in preclinical studies of hedgehog (Hh) pathway inhibitors were not substantiated in early phase clinical studies of vismodegib in children. Consequently, vismodegib advanced into pediatric trials for malignancies suspected of being driven...

Cite
Robinson GW, Kaste SC, Chemaitilly W, et al. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017;8(41):69295-69302doi: 10.18632/oncotarget.20619.
Robinson, G. W., Kaste, S. C., Chemaitilly, W., Bowers, D. C., Laughton, S., Smith, A., Gottardo, N. G., Partap, S., Bendel, A., Wright, K. D., Orr, B. A., Warner, W. C., Onar-Thomas, A., & Gajjar, A. (2017). Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget, 8(41), 69295-69302. https://doi.org/10.18632/oncotarget.20619
Robinson, Giles W, et al. "Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor." Oncotarget vol. 8,41 (2017): 69295-69302. doi: https://doi.org/10.18632/oncotarget.20619
Robinson GW, Kaste SC, Chemaitilly W, Bowers DC, Laughton S, Smith A, Gottardo NG, Partap S, Bendel A, Wright KD, Orr BA, Warner WC, Onar-Thomas A, Gajjar A. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017 Sep 01;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19. PMID: 29050204; PMCID: PMC5642479.
Copy Download .nbib Format: NLM
A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, Baxter PA, Hwang EI, Bukowinski A, Dorris K, Hoffman L, Waanders AJ, Karajannis MA, Stewart CF, Onar-Thomas A, Fouladi M, Dunkel IJ.
PMID: 33547201
Clin Cancer Res. 2021 May 01;27(9):2442-2451. doi: 10.1158/1078-0432.CCR-20-4078. Epub 2021 Feb 05.

PURPOSE: Genomic aberrations in cell cycle and PI3K pathways are commonly observed in pediatric brain tumors. This study determined the MTD/recommended phase II dose (RP2D) of ribociclib and everolimus and characterized single-agent ribociclib concentrations in plasma and tumor in...

Cite
DeWire MD, Fuller C, Campagne O, et al. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res. 2021;27(9):2442-2451doi: 10.1158/1078-0432.CCR-20-4078.
DeWire, M. D., Fuller, C., Campagne, O., Lin, T., Pan, H., Young Poussaint, T., Baxter, P. A., Hwang, E. I., Bukowinski, A., Dorris, K., Hoffman, L., Waanders, A. J., Karajannis, M. A., Stewart, C. F., Onar-Thomas, A., Fouladi, M., & Dunkel, I. J. (2021). A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2442-2451. https://doi.org/10.1158/1078-0432.CCR-20-4078
DeWire, Mariko D, et al. "A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2442-2451. doi: https://doi.org/10.1158/1078-0432.CCR-20-4078
DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, Baxter PA, Hwang EI, Bukowinski A, Dorris K, Hoffman L, Waanders AJ, Karajannis MA, Stewart CF, Onar-Thomas A, Fouladi M, Dunkel IJ. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res. 2021 May 01;27(9):2442-2451. doi: 10.1158/1078-0432.CCR-20-4078. Epub 2021 Feb 05. PMID: 33547201; PMCID: PMC8132306.
Copy Download .nbib Format: NLM
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.

Cancer cell

Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P, Boop FA, Stewart CF, Harreld JH, Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA.
PMID: 34678152
Cancer Cell. 2021 Nov 08;39(11):1519-1530.e4. doi: 10.1016/j.ccell.2021.09.012. Epub 2021 Oct 21.

Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the cerebellum, succumb to their disease. Conventional response monitoring by imaging and cerebrospinal fluid (CSF) cytology remains challenging, and a marker for measurable residual disease (MRD) is lacking....

Cite
Liu APY, Smith KS, Kumar R, et al. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021;39(11):1519-1530.e4doi: 10.1016/j.ccell.2021.09.012.
Liu, A. P. Y., Smith, K. S., Kumar, R., Paul, L., Bihannic, L., Lin, T., Maass, K. K., Pajtler, K. W., Chintagumpala, M., Su, J. M., Bouffet, E., Fisher, M. J., Gururangan, S., Cohn, R., Hassall, T., Hansford, J. R., Klimo, P., Boop, F. A., Stewart, C. F., Harreld, J. H., Merchant, T. E., Tatevossian, R. G., Neale, G., Lear, M., Klco, J. M., Orr, B. A., Ellison, D. W., Gilbertson, R. J., Onar-Thomas, A., Gajjar, A., Robinson, G. W., & Northcott, P. A. (2021). Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer cell, 39(11), 1519-1530.e4. https://doi.org/10.1016/j.ccell.2021.09.012
Liu, Anthony P Y, et al. "Serial assessment of measurable residual disease in medulloblastoma liquid biopsies." Cancer cell vol. 39,11 (2021): 1519-1530.e4. doi: https://doi.org/10.1016/j.ccell.2021.09.012
Liu APY, Smith KS, Kumar R, Paul L, Bihannic L, Lin T, Maass KK, Pajtler KW, Chintagumpala M, Su JM, Bouffet E, Fisher MJ, Gururangan S, Cohn R, Hassall T, Hansford JR, Klimo P, Boop FA, Stewart CF, Harreld JH, Merchant TE, Tatevossian RG, Neale G, Lear M, Klco JM, Orr BA, Ellison DW, Gilbertson RJ, Onar-Thomas A, Gajjar A, Robinson GW, Northcott PA. Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell. 2021 Nov 08;39(11):1519-1530.e4. doi: 10.1016/j.ccell.2021.09.012. Epub 2021 Oct 21. PMID: 34678152.
Copy Download .nbib Format: NLM
A Simulation Based Evaluation of the Asymptotic Power Formulae for Cox Models in Small Sample Cases.

The American statistician

Kocak M, Onar-Thomas A.
PMID: 24115780
Am Stat. 2012;66(3):173-179. doi: 10.1080/00031305.2012.703873.

Cox proportional hazards (PH) models are commonly used in medical research to investigate the associations between covariates and time to event outcomes. It is frequently noted that with less than ten events per covariate, these models produce spurious results,...

Cite
Kocak M, Onar-Thomas A. A Simulation Based Evaluation of the Asymptotic Power Formulae for Cox Models in Small Sample Cases. Am Stat. 2012;66(3):173-179doi: 10.1080/00031305.2012.703873.
Kocak, M., & Onar-Thomas, A. (2012). A Simulation Based Evaluation of the Asymptotic Power Formulae for Cox Models in Small Sample Cases. The American statistician, 66(3), 173-179. https://doi.org/10.1080/00031305.2012.703873
Kocak, Mehmet, and Onar-Thomas, Arzu. "A Simulation Based Evaluation of the Asymptotic Power Formulae for Cox Models in Small Sample Cases." The American statistician vol. 66,3 (2012): 173-179. doi: https://doi.org/10.1080/00031305.2012.703873
Kocak M, Onar-Thomas A. A Simulation Based Evaluation of the Asymptotic Power Formulae for Cox Models in Small Sample Cases. Am Stat. 2012;66(3):173-179. doi: 10.1080/00031305.2012.703873. PMID: 24115780; PMCID: PMC3791864.
Copy Download .nbib Format: NLM
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research

Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A.
PMID: 33737307
Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18.

PURPOSE: Report relevance of molecular groups to clinicopathologic features, germline MATERIALS AND METHODS: Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; RESULTS: Twenty-four participants (32%) were alive at time of...

Cite
Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021;27(10):2879-2889doi: 10.1158/1078-0432.CCR-20-4731.
Upadhyaya, S. A., Robinson, G. W., Onar-Thomas, A., Orr, B. A., Johann, P., Wu, G., Billups, C. A., Tatevossian, R. G., Dhanda, S. K., Srinivasan, A., Broniscer, A., Qaddoumi, I., Vinitsky, A., Armstrong, G. T., Bendel, A. E., Hassall, T., Partap, S., Fisher, P. G., Crawford, J. R., Chintagumpala, M., Bouffet, E., Gururangan, S., Mostafavi, R., Sanders, R. P., Klimo, P., Patay, Z., Indelicato, D. J., Nichols, K. E., Boop, F. A., Merchant, T. E., Kool, M., Ellison, D. W., & Gajjar, A. (2021). Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2879-2889. https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya, Santhosh A, et al. "Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2879-2889. doi: https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18. PMID: 33737307; PMCID: PMC8127412.
Copy Download .nbib Format: NLM
A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.

Clinical cancer research : an official journal of the American Association for Cancer Research

DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, Baxter PA, Hwang EI, Bukowinski A, Dorris K, Hoffman L, Waanders AJ, Karajannis MA, Stewart CF, Onar-Thomas A, Fouladi M, Dunkel IJ.
PMID: 33547201
Clin Cancer Res. 2021 May 01;27(9):2442-2451. doi: 10.1158/1078-0432.CCR-20-4078. Epub 2021 Feb 05.

PURPOSE: Genomic aberrations in cell cycle and PI3K pathways are commonly observed in pediatric brain tumors. This study determined the MTD/recommended phase II dose (RP2D) of ribociclib and everolimus and characterized single-agent ribociclib concentrations in plasma and tumor in...

Cite
DeWire MD, Fuller C, Campagne O, et al. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res. 2021;27(9):2442-2451doi: 10.1158/1078-0432.CCR-20-4078.
DeWire, M. D., Fuller, C., Campagne, O., Lin, T., Pan, H., Young Poussaint, T., Baxter, P. A., Hwang, E. I., Bukowinski, A., Dorris, K., Hoffman, L., Waanders, A. J., Karajannis, M. A., Stewart, C. F., Onar-Thomas, A., Fouladi, M., & Dunkel, I. J. (2021). A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(9), 2442-2451. https://doi.org/10.1158/1078-0432.CCR-20-4078
DeWire, Mariko D, et al. "A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,9 (2021): 2442-2451. doi: https://doi.org/10.1158/1078-0432.CCR-20-4078
DeWire MD, Fuller C, Campagne O, Lin T, Pan H, Young Poussaint T, Baxter PA, Hwang EI, Bukowinski A, Dorris K, Hoffman L, Waanders AJ, Karajannis MA, Stewart CF, Onar-Thomas A, Fouladi M, Dunkel IJ. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clin Cancer Res. 2021 May 01;27(9):2442-2451. doi: 10.1158/1078-0432.CCR-20-4078. Epub 2021 Feb 05. PMID: 33547201; PMCID: PMC8132306.
Copy Download .nbib Format: NLM
Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.

Cancer chemotherapy and pharmacology

Reddick SJ, Campagne O, Huang J, Onar-Thomas A, Broniscer A, Gajjar A, Stewart CF.
PMID: 31912224
Cancer Chemother Pharmacol. 2020 Feb;85(2):475. doi: 10.1007/s00280-019-04026-7.

In the original publication of the article, the authors wish to note an error in the section "Funding".

Cite
Reddick SJ, Campagne O, Huang J, et al. Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer Chemother Pharmacol. 2020;85(2):475doi: 10.1007/s00280-019-04026-7.
Reddick, S. J., Campagne, O., Huang, J., Onar-Thomas, A., Broniscer, A., Gajjar, A., & Stewart, C. F. (2020). Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer chemotherapy and pharmacology, 85(2), 475. https://doi.org/10.1007/s00280-019-04026-7
Reddick, Samuel J, et al. "Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors." Cancer chemotherapy and pharmacology vol. 85,2 (2020): 475. doi: https://doi.org/10.1007/s00280-019-04026-7
Reddick SJ, Campagne O, Huang J, Onar-Thomas A, Broniscer A, Gajjar A, Stewart CF. Correction to: Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors. Cancer Chemother Pharmacol. 2020 Feb;85(2):475. doi: 10.1007/s00280-019-04026-7. PMID: 31912224.
Copy Download .nbib Format: NLM
Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Germinoma: A Children's Oncology Group Study.

Neuro-oncology

Bartels U, Onar-Thomas A, Patel SK, Shaw D, Fangusaro J, Dhall G, Souweidane M, Bhatia A, Embry L, Trask CL, Murphy ES, MacDonald S, Wu S, Boyett JM, Leary S, Fouladi M, Gajjar A, Khatua S.
PMID: 34850169
Neuro Oncol. 2021 Nov 29; doi: 10.1093/neuonc/noab270. Epub 2021 Nov 29.

BACKGROUND: The study aimed to evaluate whether simplified chemotherapy followed by dose-reduced irradiation was effective for treating patients (ages 3-21 years) with localized germinoma. The primary endpoint was 3-year progression free survival (PFS) rate.METHODS: Patients with a complete response...

Cite
Bartels U, Onar-Thomas A, Patel SK, et al. Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Germinoma: A Children's Oncology Group Study. Neuro Oncol. 2021;doi: 10.1093/neuonc/noab270.
Bartels, U., Onar-Thomas, A., Patel, S. K., Shaw, D., Fangusaro, J., Dhall, G., Souweidane, M., Bhatia, A., Embry, L., Trask, C. L., Murphy, E. S., MacDonald, S., Wu, S., Boyett, J. M., Leary, S., Fouladi, M., Gajjar, A., & Khatua, S. (2021). Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Germinoma: A Children's Oncology Group Study. Neuro-oncology, . https://doi.org/10.1093/neuonc/noab270
Bartels, Ute, et al. "Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Germinoma: A Children's Oncology Group Study." Neuro-oncology vol. (2021). doi: https://doi.org/10.1093/neuonc/noab270
Bartels U, Onar-Thomas A, Patel SK, Shaw D, Fangusaro J, Dhall G, Souweidane M, Bhatia A, Embry L, Trask CL, Murphy ES, MacDonald S, Wu S, Boyett JM, Leary S, Fouladi M, Gajjar A, Khatua S. Phase II Trial of Response-Based Radiation Therapy for Patients with Localized Germinoma: A Children's Oncology Group Study. Neuro Oncol. 2021 Nov 29; doi: 10.1093/neuonc/noab270. Epub 2021 Nov 29. PMID: 34850169.
Copy Download .nbib Format: NLM
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG.

Neuro-oncology advances

Tinkle CL, Broniscer A, Chiang J, Campagne O, Huang J, Orr BA, Li X, Patay Z, Zhang J, Baker SJ, Merchant TE, Jain V, Onar-Thomas A, Stewart CF, Wetmore C, Gajjar A.
PMID: 34993482
Neurooncol Adv. 2021 Dec 01;3(1):vdab179. doi: 10.1093/noajnl/vdab179. eCollection 2021.

BACKGROUND: Platelet-derived growth factor receptor (PDGFR) signaling has been directly implicated in pediatric high-grade gliomagenesis. This study evaluated the safety and tolerability of crenolanib, a potent, selective inhibitor of PDGFR-mediated phosphorylation, in pediatric patients with high-grade glioma (HGG).METHODS: We...

Cite
Tinkle CL, Broniscer A, Chiang J, et al. Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neurooncol Adv. 2021;3(1):vdab179doi: 10.1093/noajnl/vdab179.
Tinkle, C. L., Broniscer, A., Chiang, J., Campagne, O., Huang, J., Orr, B. A., Li, X., Patay, Z., Zhang, J., Baker, S. J., Merchant, T. E., Jain, V., Onar-Thomas, A., Stewart, C. F., Wetmore, C., & Gajjar, A. (2021). Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neuro-oncology advances, 3(1), vdab179. https://doi.org/10.1093/noajnl/vdab179
Tinkle, Christopher L, et al. "Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG." Neuro-oncology advances vol. 3,1 (2021): vdab179. doi: https://doi.org/10.1093/noajnl/vdab179
Tinkle CL, Broniscer A, Chiang J, Campagne O, Huang J, Orr BA, Li X, Patay Z, Zhang J, Baker SJ, Merchant TE, Jain V, Onar-Thomas A, Stewart CF, Wetmore C, Gajjar A. Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG. Neurooncol Adv. 2021 Dec 01;3(1):vdab179. doi: 10.1093/noajnl/vdab179. eCollection 2021. PMID: 34993482; PMCID: PMC8717895.
Copy Download .nbib Format: NLM
Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.

Neuro-oncology

Lucas JT, Tinkle CL, Huang J, Onar-Thomas A, Srinivasan S, Tumlin P, Becksfort J, Klimo P, Boop FA, Robinson GW, Orr BA, Harreld JH, Krasin MJ, Northcott PA, Ellison DW, Gajjar A, Merchant TE.
PMID: 34894262
Neuro Oncol. 2021 Dec 11; doi: 10.1093/neuonc/noab284. Epub 2021 Dec 11.

BACKGROUND: We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.METHODS: 155 pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of...

Cite
Lucas JT, Tinkle CL, Huang J, et al. Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro Oncol. 2021;doi: 10.1093/neuonc/noab284.
Lucas, J. T., Tinkle, C. L., Huang, J., Onar-Thomas, A., Srinivasan, S., Tumlin, P., Becksfort, J., Klimo, P., Boop, F. A., Robinson, G. W., Orr, B. A., Harreld, J. H., Krasin, M. J., Northcott, P. A., Ellison, D. W., Gajjar, A., & Merchant, T. E. (2021). Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-oncology, . https://doi.org/10.1093/neuonc/noab284
Lucas, John T, et al. "Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study." Neuro-oncology vol. (2021). doi: https://doi.org/10.1093/neuonc/noab284
Lucas JT, Tinkle CL, Huang J, Onar-Thomas A, Srinivasan S, Tumlin P, Becksfort J, Klimo P, Boop FA, Robinson GW, Orr BA, Harreld JH, Krasin MJ, Northcott PA, Ellison DW, Gajjar A, Merchant TE. Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro Oncol. 2021 Dec 11; doi: 10.1093/neuonc/noab284. Epub 2021 Dec 11. PMID: 34894262.
Copy Download .nbib Format: NLM
Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.

Neuro-oncology

Lucas JT, Tinkle CL, Huang J, Onar-Thomas A, Srinivasan S, Tumlin P, Becksfort J, Klimo P, Boop FA, Robinson GW, Orr BA, Harreld JH, Krasin MJ, Northcott PA, Ellison DW, Gajjar A, Merchant TE.
PMID: 34894262
Neuro Oncol. 2021 Dec 11; doi: 10.1093/neuonc/noab284. Epub 2021 Dec 11.

BACKGROUND: We characterize the patterns of progression across medulloblastoma (MB) clinical risk and molecular subgroups from SJMB03, a Phase III clinical trial.METHODS: 155 pediatric patients with newly diagnosed MB were treated on a prospective, multi-center phase III trial of...

Cite
Lucas JT, Tinkle CL, Huang J, et al. Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro Oncol. 2021;doi: 10.1093/neuonc/noab284.
Lucas, J. T., Tinkle, C. L., Huang, J., Onar-Thomas, A., Srinivasan, S., Tumlin, P., Becksfort, J., Klimo, P., Boop, F. A., Robinson, G. W., Orr, B. A., Harreld, J. H., Krasin, M. J., Northcott, P. A., Ellison, D. W., Gajjar, A., & Merchant, T. E. (2021). Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-oncology, . https://doi.org/10.1093/neuonc/noab284
Lucas, John T, et al. "Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study." Neuro-oncology vol. (2021). doi: https://doi.org/10.1093/neuonc/noab284
Lucas JT, Tinkle CL, Huang J, Onar-Thomas A, Srinivasan S, Tumlin P, Becksfort J, Klimo P, Boop FA, Robinson GW, Orr BA, Harreld JH, Krasin MJ, Northcott PA, Ellison DW, Gajjar A, Merchant TE. Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro Oncol. 2021 Dec 11; doi: 10.1093/neuonc/noab284. Epub 2021 Dec 11. PMID: 34894262.
Copy Download .nbib Format: NLM
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials.

Clinical cancer research : an official journal of the American Association for Cancer Research

Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A.
PMID: 33737307
Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18.

PURPOSE: Report relevance of molecular groups to clinicopathologic features, germline MATERIALS AND METHODS: Seventy-four participants with newly diagnosed ATRT were treated in two trials: infants (SJYC07: age < 3 years; RESULTS: Twenty-four participants (32%) were alive at time of...

Cite
Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021;27(10):2879-2889doi: 10.1158/1078-0432.CCR-20-4731.
Upadhyaya, S. A., Robinson, G. W., Onar-Thomas, A., Orr, B. A., Johann, P., Wu, G., Billups, C. A., Tatevossian, R. G., Dhanda, S. K., Srinivasan, A., Broniscer, A., Qaddoumi, I., Vinitsky, A., Armstrong, G. T., Bendel, A. E., Hassall, T., Partap, S., Fisher, P. G., Crawford, J. R., Chintagumpala, M., Bouffet, E., Gururangan, S., Mostafavi, R., Sanders, R. P., Klimo, P., Patay, Z., Indelicato, D. J., Nichols, K. E., Boop, F. A., Merchant, T. E., Kool, M., Ellison, D. W., & Gajjar, A. (2021). Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2879-2889. https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya, Santhosh A, et al. "Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2879-2889. doi: https://doi.org/10.1158/1078-0432.CCR-20-4731
Upadhyaya SA, Robinson GW, Onar-Thomas A, Orr BA, Johann P, Wu G, Billups CA, Tatevossian RG, Dhanda SK, Srinivasan A, Broniscer A, Qaddoumi I, Vinitsky A, Armstrong GT, Bendel AE, Hassall T, Partap S, Fisher PG, Crawford JR, Chintagumpala M, Bouffet E, Gururangan S, Mostafavi R, Sanders RP, Klimo P, Patay Z, Indelicato DJ, Nichols KE, Boop FA, Merchant TE, Kool M, Ellison DW, Gajjar A. Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 May 15;27(10):2879-2889. doi: 10.1158/1078-0432.CCR-20-4731. Epub 2021 Mar 18. PMID: 33737307; PMCID: PMC8127412.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries